Stockwinners Market Radar for May 28, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:17 EDT Attorneys announce over $500M pact with Eli Lilly to settle class-action suit - Attorneys at Hagens Berman and Carella Byrne Cecchi Olstein Brody & Agnello announced a settlement with insulin-maker Eli Lilly worth more than $500M, culminating a class-action lawsuit on behalf of insulin purchasers alleging systematic overpricing of insulin. "This settlement will bring immense, forward-looking relief, especially for those who are underinsured or paying with co-insurance - those most in need of assistance paying for the medications they need to live," said Steve Berman, managing partner and co-founder of Hagens Berman and court-appointed co-lead counsel representing insulin purchasers in the lawsuit. "Those paying out-of-pocket for insulin will receive four years of insulin at a reduced price under the settlement."

17:33 EDT Iovance Biotherapeutics announces FDA acceptance of BLA of Lifileucel - Iovance Biotherapeutics announced that the U.S. Food and Drug Administration accepted its Biologics License Application for lifileucel for patients with advanced melanoma. The FDA granted lifileucel Priority Review and assigned November 25, 2023 as the target action date for a decision under the Prescription Drug User Fee Act. The FDA is not currently planning to hold an advisory committee meeting to discuss this application and, after a preliminary review, has not at this time identified any potential review issues. Lifileucel is a TIL therapy intended for patients with advanced melanoma who progressed on or after prior anti-PD-1/L1 therapy and targeted therapy, where applicable. There are no FDA approved therapies in this treatment setting. Under the FDA's guidance, Priority Review allows for an six-month review from the time of BLA acceptance for treatments that, if approved, are substantially safer or more effective than standard of care therapies. The FDA also previously granted a Regenerative Medicine Advanced Therapy designation for lifileucel in advanced melanoma. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, "The BLA acceptance is a significant milestone in our mission to deliver lifileucel as the first individualized, one-time cell therapy for a solid tumor. The FDA's commitment to a six-month Priority Review validates the unmet need and urgency for new treatment options for patients with advanced melanoma who have progressed on or after standard of care therapies. I am grateful for the patients and physicians who took part in all our clinical trials, as well as the Iovance team for their outstanding work on our first BLA filing. We look forward to continuing our collaboration with the FDA during the BLA review cycle, while continuing to execute our pre-commercialization activities and advancing our robust TIL pipeline."

16:49 EDT Cboe Global Markets director Ratterman sells 15,000 common shares - In a regulatory filing, Cboe Global Markets director Joseph Ratterman disclosed the sale of 15,000 common shares of the company on May 24 at a price of $135.96 per share.

16:31 EDT Smart Powerr receives noncompliance notification from Nasdaq - Smart Powerr announced that it received written notification from Listing Qualifications Department of Nasdaq that, as a result of not having timely filed its quarterly report on Form 10-Q for the year ended March 31, the company does not comply with the Nasdaq Listing Rule 5250, which requires timely filing of periodic financial reports with the U.S. Securities and Exchange Commission.

16:16 EDT TransDigm names Mike Lisman, Joel Reiss co-COOs, Wynne named CFO - TransDigm Group Incorporated announced the upcoming retirement of Chief Operating Officer Jorge L. Valladares III, the appointment of Mr. Valladares to the company's Board of Directors, the appointment of Mike Lisman and Joel Reiss as Co-Chief Operating Officers, and the appointment of Sarah Wynne as Chief Financial Officer. Valladares will retire at the end of the TransDigm's 2023 fiscal year and has served as the Company's Chief Operating Officer for the past four years.Lisman, the Company's Chief Financial Officer, and Mr. Reiss, an Executive Vice President of the Company, have now assumed the roles of co-COOs. Wynne has assumed the role of Chief Financial Officer, after having served as TransDigm's Chief Accounting Officer for the past five years. She brings strong experience in operational and GAAP accounting to her new assignment and has been with TransDigm for 20 years.

16:14 EDT Green Plains CEO sells 42,000 common shares - In a regulatory filing, Green Plains president and CEO Todd Becker disclosed the sale of 42,000 common shares of the company on May 24 at a price of $31.78 per share.

16:08 EDT East Resources Acquisition receives expected Nasdaq notice over delayed report - East Resources Acquisition Company announced that, on May 24, 2023, it received a notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC stating that the Company is not in compliance with NASDAQ Listing Rule 5250(c)(1)because the company failed to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 with the Securities and Exchange Commission. The Notice has no immediate effect on the listing or trading of the company's securities on the NASDAQ. As previously disclosed in the Form 12b-25 filed on May 15, 2023 by the company, the company determined that it was unable, without unreasonable effort or expense, to file the Form 10-Q by the required date of May 15, 2023. The company has since satisfied this obligation by filing its Form 10-Q on May 25, 2023.

16:07 EDT Lexicon announces FDA approval of INPEFA for treatment of heart failure - Lexicon Pharmaceuticals announced that the U.S. Food and Drug Administration has approved INPEFA, a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. The broad label encompasses heart failure patients across the full range of left ventricular ejection fraction, including preserved ejection fraction and reduced ejection fraction, and for patients with or without diabetes. "The approval of INPEFA along with the breadth of the label, is a major milestone in Lexicon's path to fulfilling its mission of pioneering medicines that transform patients' lives," said Lonnel Coats, Lexicon's chief executive officer. "We expect this important innovation to be commercially available in the U.S. market by the end of June 2023."

15:48 EDT TCRC ratifies Canadian National collective agreement - Canadian National announced that the Teamsters Canada Rail Conference has ratified its collective agreement with the Company. The union represents approximately 6,000 CN Locomotive Engineers, Conductors, Yard Conductors, and Yard Coordinators working in Canada. "We are pleased that TCRC members have ratified the collective agreement reached earlier this year," said CN president and CEO Tracy Robinson. "We thank the TCRC leadership for their engagement throughout this process. We remain committed to working with this important group to ensure continued service for our customers and improved working conditions for our team members."

15:19 EDT Funky Buddha Brewery founders to reacquire company from Constellation Brands - The founders of Funky Buddha Brewery - Ryan and KC Sentz - are reacquiring their business from Constellation Brands, the company announced. "Both the Sentzs and Constellation agreed that now is the ideal time for the original owners to reclaim control of the company and focus on beverage innovation, new consumer experiences, and additional product lines. Its flagship beer portfolio, including Floridian and Hop Gun, will remain available for distribution, and the founders are excited to introduce new products," the company stated. "We enjoyed working with Constellation and we learned a lot from them. As we embark on the next chapter, we plan to push boundaries and create entirely new drinking experiences in beer and beyond. We'll be serving good vibes on tap for many years to come," said Ryan Sentz, owner and co-founder. The brand was acquired by Constellation Brands in 2017. The reacquisition of Funky Buddha Brewery by the Sentz brothers is targeted for June 2023.

14:33 EDT Titan Medical enters $7.5M upfront license agreement with Intuitive Surgical - Titan Medical (TMDIF) announced today that the company has entered into a license agreement with Intuitive Surgical (ISRG) for an upfront payment of $7.5M in respect of certain intellectual property of Titan. Under the Agreement, Titan has granted Intuitive a non-exclusive license to all of Titan's IP with the exception of the IP that is exclusively licensed to another party under a June 2020 license agreement. Titan retains ownership of the licensed IP, along with the associated rights including the right to continue to develop and commercialize the technologies covered by the licensed IP and the right to license the IP to other third parties, the company said in a statement.

14:03 EDT DLocal says article published by Infobae includes 'misleading allegations' - dLocal Limited issued the following response to a press article: "Today we were subject to a set of misleading allegations in an article published by Infobae, who has not reached out to the company for comments, about alleged non compliance with expatriation rules in Argentina. dLocal operates in the payments industry and is regulated by government authorities across its 40 geographies. The referred article is factually incorrect: dLocal processes payments for global merchants. Our activities are subject to government regulations specific to each currency being exchanged. In Argentina, expatriation of funds are conducted through regulated parties that follow the Central Bank of Argentina rules, containing detailed information at a payment transaction level. Funds expatriated from Argentina are settled to global merchants, net of taxes; As part of our day to day activities, we are in close contact with authorities and there is a continuous flow of information. To the extent we are notified by authorities in Argentina, or any other geography, we engage meaningfully and cooperate with any requests from regulatory authorities. As of today, we have not been notified by any Argentinian authority regarding a foreign exchange investigation; We continue to process payments normally in Argentina. We have been operating in the country since 2016 and have a solid local presence with over 150 employees across numerous offices. We will maintain our focus on delivering outstanding service and results for our customers, shareholders and other stakeholders. We will not be distracted by misleading allegations. dLocal is committed to the integrity of all its business activities and will continue to focus on providing the best and most comprehensive solution for our global merchants in each market in which we operate."

13:02 EDT Baker Hughes reports U.S. rig count down 9 to 711 rigs - Baker Hughes reports that the U.S. rig count is down 9 from last week to 711 with oil rigs down 5 to 570, gas rigs down 4 to 137 and miscellaneous rigs unchanged at 4. The U.S. Rig Count is down 16 rigs from last year's count of 727 with oil rigs down 4, gas rigs down 14 and miscellaneous up 2. The U.S. Offshore Rig Count is down 1 to 20, up 4 year-over-year. The Canada Rig Count is up 2 from last week to 87, with oil rigs up 3 to 42, gas rigs down 1 to 45. The Canada Rig Count is down 16 rigs from last year's count of 103 with oil down 13, gas rigs down 3.

12:56 EDT Bit Origin to effect reverse stock split on May 30 - Bit Origin Ltd announced that it has resolved to effect a reverse stock split of the company's ordinary shares and has determined the ratio to be 1-for-30. The company's shareholders approved the reverse stock split and granted the company's Board of Directors the authority to determine the exact split ratio at the company's annual meeting of shareholders held on May 18, 2023. Bit Origin's ordinary shares will begin trading on an adjusted basis giving effect to the reverse stock split on May 30, 2023 under the existing ticker symbol "BTOG". The new CUSIP number of the company's ordinary shares will be G21621118. "Our Company went through a complete business transformation into crypto mining over the past year. The reverse stock split will better align Bit Origin's number of shares outstanding with company of our size and scope," said Lucas Wang, Chairman and Chief Executive Officer of the Company.

12:25 EDT ConocoPhillips to also pay contigent payments of up to $325M

12:22 EDT ConocoPhillips to buy remaining 50% interest in Surmont for $3B

12:00 EDT PagSeguro Digital falls -14.9% - PagSeguro Digital is down -14.9%, or -$1.81 to $10.31.

12:00 EDT Virgin Galactic falls -17.0% - Virgin Galactic is down -17.0%, or -69c to $3.36.

12:00 EDT MediaAlpha rises 30.0% - MediaAlpha is up 30.0%, or $2.28 to $9.88.

11:40 EDT Pfizer, BioNTech in agreement with EU to reduce COVID vaccine volumes - Pfizer (PFE) and BioNTech (BNTX) announced they have reached an agreement with the European Commission to amend their existing contract to deliver COVID-19 vaccines to the European Union. The amended agreement includes rephasing of delivery of doses annually through 2026. In addition, the agreement includes an aggregate volume reduction, "providing additional flexibility for EU Member States," the companies said in a statement. The European Commission will maintain access to future adapted COVID-19 vaccines and the ability to donate doses, in alignment with the original agreement. Reference Link

11:33 EDT 8x8, RingCentral higher as activist Sylebra says may engage in talks - Sylebra Capital, which disclosed that it holds a 12.37% stake in 8x8 (EGHT) and an 8.68% stake in RingCentral (RNG) in separate Schedule 13D filings with the SEC, stated that it intends to "engage in discussions with the [companies] and consider exploring and/or developing plans (whether preliminary or final) that may relate to, among other things, the operations, governance, management, business, assets, financial condition, corporate structure and strategic merger and acquisition plans of the [companies]." The filing stated that such discussions "may include proposals regarding possible strategic transactions including possible business combinations." In late morning trading, shares of 8x* are up 51c, or 14%, to $4.17, while shares of RingCentral are up $1.89, or 6%, to $31.39.

11:27 EDT 8x8 holder Sylebra intends to seek talks with managment - Sylebra Capital, which disclosed that it holds a 12.37% stake in 8x8, previously filed a Schedule 13G, as amended, on February 14, but is now filing Schedule 13D with the SEC to supersede their previously filed Schedule 13G to "report a change in their intentions." Sylebra "intend to engage in discussions with the Issuer and consider exploring and/or developing plans (whether preliminary or final) that may relate to, among other things, the operations, governance, management, business, assets, financial condition, corporate structure and strategic merger and acquisition plans of the Issuer. Such discussions may include proposals regarding possible strategic transactions including possible business combinations," the filing stated.

10:00 EDT Virgin Galactic falls -14.0% - Virgin Galactic is down -14.0%, or -56c to $3.48.

10:00 EDT Big Lots falls -18.7% - Big Lots is down -18.7%, or -$1.35 to $5.86.

10:00 EDT Arcus Biosciences rises 22.6% - Arcus Biosciences is up 22.6%, or $3.96 to $21.46.

09:56 EDT Immix Biopharma's Nexcella commences NXC-201 engineering batches - Nexcella announced the commencement of CAR-T NXC-201 Engineering Batches at its U.S. Manufacturing Site. These U.S. engineering batches will support the planned U.S. expansion of the Company's ongoing Phase 1b/2a NEXICART-1 study of its novel BCMA-targeted chimeric antigen receptor T cell therapy NXC-201. This manufacturing milestone represents a crucial next step in transferring the Company's existing CAR-T GMP manufacturing process to the United States following the selection of a U.S. GMP manufacturer in February 2023.

09:47 EDT X Financial falls -9.6% - X Financial is down -9.6%, or -34c to $3.22.

09:47 EDT Big Lots falls -12.8% - Big Lots is down -12.8%, or -92c to $6.29.

09:47 EDT MediaAlpha rises 18.8% - MediaAlpha is up 18.8%, or $1.43 to $9.03.

09:46 EDT ROC Energy Acquisition Corp trading halted, volatility trading pause

09:35 EDT Lowe's announces 5% increase to quarterly cash dividend to $1.10 per share - The board of directors for Lowe's Companies has declared a quarterly cash dividend of $1.10 per share, payable Aug. 9, 2023, to shareholders of record as of July 26, 2023. This represents a 5% increase over the company's previous dividend of $1.05 per share. "We have made tremendous strides with our Total Home strategy, which has enabled us to take market share, drive Pro loyalty, accelerate online growth and deliver value for DIY customers," said Marvin R. Ellison, Lowe's chairman, president and CEO. "Today's dividend increase reinforces our commitment to a best-in-class capital allocation strategy centered on delivering sustainable shareholder value."

09:34 EDT Malaysia's SKS Airways signs deal for 10 Embraer E195-E2 aircraft - Malaysia's SKS Airways has chosen the Embraer E195-E2 to drive its growth plans for the region. The deal for 10 E195-E2s was announced at a signing ceremony at the Langkawi International Maritime & Aerospace Exhibition. The E195-E2s will form the core of SKS Airways' expansion plans and will be based at Kuala Lumpur's city airport, Subang, from 2024. The E195-E2 jet has a range of 2,600nm, the equivalent of about seven hours of flight. The aircraft will be comfortably configured with 136 seats. SKS Airways will be the first E195-E2 operator in the Southeast Asian region, growing Embraer's E-Jets presence in the broader Asia Pacific region which currently stands close to 200.

09:30 EDT Novavax's Nuvaxovid gets positive CHMP opinion for full marketing in EU - Novavax announced that Nuvaxovid has been recommended for full Marketing Authorization for use as a primary series in individuals aged 12 and older and as a booster in individuals aged 18 and older for the prevention of COVID-19 in the European Union following a positive opinion issued by the Committee for Medicinal Products for Human Use of the European Medicines Agency. The European Commission will review the CHMP recommendation and is expected to make a final decision on the MA.

09:10 EDT Bird Global announces expansion of operations in Rome - Bird Global announced the extension of its operations in Rome, Italy. Bird, which began operations in Rome in 2020, was awarded a new three-year permit that includes expansion of its services throughout the city. The expansion is part of Rome's ongoing efforts to reduce dependence on personal automobiles and lower the city's car density. Bird is taking a leading role in this effort by providing mobility alternatives with a significantly lower carbon footprint than cars as well as partnering with the city of Rome to integrate its fleet with the current public transportation infrastructure.

09:04 EDT Digerati Technologies postpones special meeting of shareholders - Digerati Technologies filed a definitive proxy statement / final prospectus with respect to a special meeting of its stockholders to be held on Thursday, May 25, 2023 at 11:00 a.m. EDT to vote on, among other things, a proposal to adopt and approve that certain Business Combination Agreement by and among Digerati, Minority Equality Opportunities Acquisition Inc., a Delaware corporation and MEOA Merger Sub, Inc., and the business combination contemplated thereby. On May 25, 2023, Digerati determined to postpone the Special Meeting until 2:00 p.m. EDT on Wednesday, May 31, 2023.

09:03 EDT Shuttle Pharmaceuticals reports working capital balance of $9M as of March 31 - At March 31, the company had a working capital balance of $9M. The company anticipates that it has sufficient capital to fund operations into the first quarter of 2025.

09:02 EDT MingZhu Logistics enters share purchase agreement to acquire Alliance Liquor - MingZhu Logistics announced it has entered into a Share Purchase Agreement to acquire 100% equity of Alliance Liquor Investment Limited, which operates its liquor distribution business through its variable interest entity Xiamen Alliance Liquor Industry Group Co., Ltd. in China. The transaction is subject to the conditions that are customary for transactions of this type. The company and Alliance Liquor had previously announced that they entered into a non-binding memorandum of understanding on February 21, 2023, with the plan to further invest in and jointly develop a commercial liquor distribution business across China. Under terms of the SPA, MingZhu shall acquire 100% of Alliance Liquor in exchange for the issuance of 4,569,095 ordinary shares of Mingzhu upon closing. The shareholder of Alliance Liquor shall receive additional First Earnout Payment of $8,042,090 and Second Earnout Payment of $8,042,090 respectively if the net income of Alliance Liquor is no lower than $2M for the fiscal year 2023 and 2024 respectively. The acquisition is part of Mingzhu's previously announced strategic plan, under which the company announced its intention to expand into the commercial liquor distribution market given the synergies and adjacency to its existing business. This initially included cooperating with a China-based distributor of liquor and other spirits to enhance its commercial liquor distribution business across China, subject to final agreement.

08:56 EDT Diana Shipping declares quarterly dividend of 15c per share - The Company has declared a dividend on its common stock based on the Company's results of operations during the quarter ended March 31, 2023, in the amount of $0.15 per share, which will be paid in shares of the Company's common stock or, upon the election of common shareholders, in cash. The dividend will be payable on or about July 10, 2023, to all shareholders of record as of June 12, 2023. The Company has 106,437,232 common shares issued and outstanding. The Company is also re-affirming its previously announced dividend guidance that it intends to declare and pay quarterly dividends with respect to the next two quarters of 2023 in an amount of not less than $0.15 per share. The actual declaration of future dividends, the establishment of record and payment dates and the determination to pay future dividends in cash, in stock, or in a combination of cash and shares of common stock is subject to final determination by the Company's board of directors each quarter after its review of the Company's financial performance.

08:36 EDT Bristol-Myers reports CHMP opinion recommending approval for Opdivo combination - Bristol-Myers announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has recommended approval of Opdivo in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer, or NSCLC, at a high risk of recurrence in adult patients with tumor cell PD-L1 expression greater than or equal to 1%. The European Commission, or EC, which has the authority to approve medicines for the European Union, or EU, will now review the CHMP recommendation.

08:34 EDT Marinus Pharmaceuticals announces CHMP opinion recommending Ztalmy approval - Marinus Pharmaceuticals announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has adopted an opinion recommending the approval of Ztalmy oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5, or CDKL5, deficiency disorder, or CDD, in patients two to 17 years of age. Ztalmy may be continued in patients 18 years of age and older.

08:33 EDT Clever Leaves reminds shareholders of upcoming annual meeting - Clever Leaves Holdings reminds shareholders that it will hold its 2023 Annual Meeting of Shareholders on Friday, June 2, 2023 at 10:00 a.m. Eastern Time. The Annual Meeting will be in a virtual-only format. Clever Leaves reminds investors that its board has recommended that shareholders vote "FOR" the proposal to elect each of the five nominees named in the proxy statement to the Board of Directors, "FOR" the appointment of Marcum LLP as the Company's independent registered public accounting firm to serve as independent auditor for the 2023 fiscal year and "FOR" the amendment to the Company's 2020 Incentive Award Plan. Shareholders of record at the close of business on April 11, 2023 are entitled to vote at the Annual Meeting and any adjournment or postponement thereof. At the Annual Meeting, shareholders will be asked to vote on the election of the five nominees named in the proxy statement to the Board of Directors; the appointment of Marcum LLP as the Company's independent registered public accounting firm to serve as independent auditor for the 2023 fiscal year; and an amendment to the Company's 2020 Incentive Award Plan.

08:05 EDT Altria Group provides update on pending acquisition of NJOY Holdings - Altria Group announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired in connection with our previously announced pending acquisition of NJOY Holdings. Therefore, no further regulatory review by the federal antitrust authorities is required in connection with the transaction. Subject to the satisfaction of other customary closing conditions, the company expects to complete the transaction in the second quarter of 2023.

08:02 EDT Minority Equality Opportunities postpones special meeting of shareholders - On May 3, 2023, Minority Equality Opportunities Acquisition filed a definitive proxy statement / final prospectus with respect to a special meeting of its stockholders to be held on Wednesday, May 24, 2023 at 10:00 a.m. EDT to vote on, among other things, a proposal to adopt and approve that certain Business Combination Agreement by and among MEOA, Digerati Technologies and MEOA Merger Sub, Inc., and the business combination contemplated thereby. On May 24, 2023, MEOA determined to postpone the Special Meeting until 10:00 a.m. EDT on Friday, May 26, 2023. On May 25, 2023, MEOA determined to further postpone the Special Meeting until 2:00 p.m. EDT on Wednesday, May 31, 2023. The purpose of the second postponement of the Special Meeting is to allow MEOA additional time to work with The Nasdaq Stock Market regarding the halt in the trading of the securities of MEOA for "additional information requested" from the company that was announced by Nasdaq on May 24, 2023. The trading halt was imposed following volatility in the trading price and volume of MEOA's securities on the morning on Wednesday, May 24, 2023. MEOA and its advisors have been in contact with representatives of Nasdaq regarding the lifting of the trading halt and the approval by Nasdaq of the listing application for the securities of the combined company following the closing of the Business Combination. MEOA and Digerati will continue to work on closing the Business Combination as soon as possible following its approval by the stockholders of each of MEOA and Digerati and the satisfaction or waiver of any applicable closing conditions. Also, as noted in MEOA's press release dated May 24, 2023 and in the Current Report on Form 8-K that MEOA filed with the Securities and Exchange Commission on that date, based upon the preliminary reports that have been provided to MEOA, the holders of an aggregate of 728,815 public shares of MEOA's Class A common stock have submitted requests that their public shares be redeemed in connection with the Special Meeting, with these redemptions only taking effect upon the closing of the Business Combination. Those stockholders who submitted requests that their shares be redeemed may withdraw such redemption requests, with MEOA's consent, at any time until the closing of the Business Combination. To date, stockholders holding an aggregate of 60,455 public shares that were submitted for redemption have withdrawn such requests, thereby increasing the number of MEOA public shares that will remain outstanding after the closing of the Business Combination to 112,468.

07:42 EDT MiX Telematics passes 1M active subscribers - MiX Telematics announced that the business has accumulated more than 1M active subscribers across their combined fleet and consumer customer base. This significant milestone comes on the back of continued subscriber growth throughout the financial year ending March 31. "Closing out the fiscal year, we are exceptionally proud to have surpassed this significant milestone. We also expanded our adjusted EBITDA margin to 25% and continue to generate strong, positive free cash flow," said CEO Stefan Joselowitz. MiX Telematics has customers in more than 120 countries globally and provides consumers and commercial fleets of all sizes with solutions for efficiency, safety, compliance, security and sustainability. Total revenue for the year was $145M, up 10% year-over-year at constant currency. Recurring revenue made up 87% of that.

07:32 EDT Shawcor awarded over C$110M pipe coating contract in South America - Shawcor announced that its pipe coating division, Pipeline Performance Group, has received a formal contract award for a development project, located offshore in South America. The Company had previously announced its conditional award, pending project sanction, in late 2022. Shawcor will provide thermal insulation and anticorrosion coating services from a Western Hemisphere facility. Project initiation is expected to begin in the fourth quarter of 2023. The coating value of this project is estimated to exceed C$110M.

07:09 EDT AstraZeneca announces results from Imfinzi plus Lynparza trial - AstraZeneca announced high-level results from the DUO-E Phase III trial showed Imfinzi in combination with platinum-based chemotherapy followed by either Imfinzi plus Lynparza or Imfinzi alone as maintenance therapy both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, or PFS, compared to standard-of-care chemotherapy alone in patients with newly diagnosed advanced or recurrent endometrial cancer. There was a greater clinical benefit observed with the combination of Imfinzi and Lynparza as maintenance treatment. Overall survival, or OS, data were immature at the time of this analysis however, a favorable trend was observed for both treatment regimens.

07:06 EDT Next Hydrogen Solutions expects resolution to resume TSX trading 'shortly' - On May 1, 2023, the Company became subject to a Cease Trade Order due to a delay in filing the year-end financial documents within the prescribed timelines. The Company filed its year-end financial documents for the year ended December 31, 2022 on May 17, 2023. On May 18, 2023, the applicable securities regulators issued a revocation order with respect to the CTO. Since the revocation order was granted, the Company has shared the necessary information with the TSX Venture Exchange and expects a resolution to resume trading of the Company's securities shortly.

07:05 EDT Big Lots reports inventory at Q1-end at $1.088B vs. $1.339B last year - The 18.8% decrease was driven by lower in-transit inventory and on-hand units.

07:04 EDT Big Lots CEO says 'macro-economic headwinds have created significant challenges' - Commenting on Q1 results announcement, Bruce Thorn, President and CEO of Big Lots stated, "Macro-economic headwinds have created significant challenges for us, which are reflected in our results and outlook. But we are confident that these headwinds will abate, and that when they do, we will see a major boost to our business. In particular, we expect furniture and seasonal to return to being the strong growth drivers for our business they have been in the past, as consumer confidence improves and as we continue to bring newness and incredible value to our assortment. While we navigate through this difficult environment, we are being very aggressive in how we are managing our business. We are significantly raising our SG&A savings target to over $100 million in 2023, and have identified over $200 million of bottom-line opportunities across gross margin and SG&A we will be pursuing over the next 18 months. Further, we are highly encouraged by the green shoots we are seeing as we work to turn the business. Notably, as a result of our efforts to introduce more bargains and treasures, marketing them better, and serving our customers well, the reactivation of lapsed customers was strong in Q1, up 9%. We are also highly focused on ensuring we have plenty of liquidity to get through this period of macroeconomic challenges. In addition to cost and inventory reduction efforts, these actions include expected further asset monetization of approximately $340 million, and the decision made by our Board of Directors this week to suspend our dividend."

07:03 EDT Compass Pathways to present long-term efficacy data on COMP360 - COMPASS Pathways announced that new long-term efficacy data of investigational COMP360 psilocybin in cancer patients with major depressive disorder will be presented at the Annual Meeting of the American Society of Clinical Oncology. More than half of the patients treated with a single dose of 25mg COMP360 psilocybin with psychological support remained in remission from their depression at 18 months post administration. The investigator-initiated study, led by Manish Agrawal, MD, at Sunstone Therapies, is believed to be the longest study of psilocybin therapy ever conducted. The trial was a phase 2, single-center, fixed-dose, open-label study in 30 patients with curable and incurable cancer and major depressive disorder. Patients were treated with a single dose of 25mg of COMP360 psilocybin, administered simultaneously in group cohorts of 3-4, with group and individual psychological support, and evaluated at 8 weeks and 18 months. Of 30 patients from the parent study, 28 were enrolled in the follow-up study. Key results: 18/28 patients demonstrated sustained clinical response from baseline to 18 months follow-up; 16/28 patients demonstrated remission of depression at 18 months. The original phase 2 study conducted by Sunstone was completed in 2021 and results were published in JAMA Oncology in April 2023. COMP360 is COMPASS's investigational proprietary formulation of synthetic psilocybin, administered in conjunction with psychological support. COMPASS is currently conducting a phase 3 clinical program of COMP360 psilocybin therapy in treatment-resistant depression, the largest of its kind ever conducted. This program follows positive results from COMPASS's phase 2b study published in the New England Journal of Medicine.

07:02 EDT Latham Group opens new fiberglass swimming pool manufacturing plant in Ontario - Latham Group announced the opening of the Company's new fiberglass manufacturing facility in Loyalist Township in Ontario, Canada, west of Kingston. "Last year, we broke ground here to build our largest fiberglass pool manufacturing plant. Today, we are thrilled to announce that this state-of-the-art facility is officially open for business," said Scott Rajeski, President, and Chief Executive Officer of Latham. "As we continue to drive the material conversion from concrete to fiberglass, the Kingston plant will allow us to better scale our operations across North America by reducing our lead times and expanding our manufacturing capabilities in attractive markets. With the Kingston facility, we look forward to being able to provide more homeowners, particularly those in the Eastern Canadian and Northeast and Upper Midwest of the United States, with our signature world-class fiberglass pools."

06:52 EDT Asbury Automotive announces new $250M share repurchase plan - Asbury Automotive Group announced its board of directors approved a new authorization to repurchase up to $250M shares of the company's common stock. Year-to-date 2023, the company has repurchased approximately 1.1M shares for approximately $211M. The company has no remaining availability to repurchase shares of common stock under the previously announced stock repurchase program.

06:49 EDT UniCredit, MasterCard expand payment partnership - UniCredit and Mastercard announced an expansion of their payment partnership. The agreement sets the stage for the start of a strong partnership consistent with the UniCredit Unlocked strategy. This is the first time any large commercial bank has put in place a single card multi market strategy of this scale in Europe. The significant broadening of the parties' relationship will deliver payment innovation and enhanced digital experiences to customers.

06:47 EDT AstraZeneca announces high-level results from DUO-E Phase III trial on Imfinzi - AstraZeneca announced positive high-level results from the DUO-E Phase III trial that showed Imfinzi in combination with platinum-based chemotherapy followed by either Imfinzi plus Lynparza or Imfinzi alone as maintenance therapy both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy alone in patients with newly diagnosed advanced or recurrent endometrial cancer. There was a greater clinical benefit observed with the combination of Imfinzi and Lynparza as maintenance treatment. Overall survival data were immature at the time of this analysis however, a favourable trend was observed for both treatment regimens. Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "These DUO-E data demonstrate for the first time the power of combining immunotherapy and a PARP inhibitor to provide meaningful clinical improvements for patients with endometrial cancer. These results underscore our ambition to redefine cancer care and we hope to bring this innovative Imfinzi and Lynparza combination to endometrial cancer patients as soon as possible."

06:42 EDT AstraZeneca says Ultomiris approved in Japan for prevention of NMOSD relapses - Ultomiris has been approved in Japan as "the first and only long-acting C5 complement inhibitor" for the prevention of relapses in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, or NMOSD, including neuromyelitis optica, AstraZeneca announced.

06:36 EDT Hibbett CEO says 'our consumers are facing a number of headwinds' - Mike Longo, President and CEO, stated, "Hibbett posted solid sales results in a challenging environment, delivering a 4.1% comparable sales increase and a total sales increase of 7.4% versus last year. We maintain very good relationships with our valued brand partners that enables us to maintain our new store growth plan and provide the product assortment to meet consumer's narrowed demand. We're investing in our already best-in-class consumer experience while also taking costs out of the business, producing leverage on SG&A of 140 basis points versus last year. We believe our product array and outstanding customer service is a competitive advantage, resulting in market share gains." Longo continued, "Our consumers are facing a number of headwinds that range from inflation to concerns over outright job loss. Of note, the total amount of the average tax refund was unfavorable to last year by approximately 10%. We believe this disproportionately impacted our consumer and impacted our sales in the important first quarter of the year. Additionally, the athletic inspired segment of our industry is carrying surplus inventory and therefore experienced an elevated level of promotional activity. As a result of the challenging retail environment, consumers are focused on a narrower range of products. The combination of these factors is a major contributor to our revised guidance for the remainder of this fiscal year. Notwithstanding our more cautious near-term consumer outlook, we believe Hibbett remains well positioned for the long-term to continue to grow and increase market share."

06:01 EDT Coherent, Mitsubishi Electric enter collaboration - Coherent and Mitsubishi Electric announced that they have signed a memorandum of understanding to collaborate on a program to scale manufacturing of SiC power electronics on a 200 mm technology platform. To meet the rapidly growing demand, Mitsubishi Electric announced an investment of approximately 260B yen in the five-year period ending March 2026. A major portion of the investment, approximately 100B yen, will be used to construct a new plant for SiC power devices, based on a 200 mm technology platform, and enhance related production facilities. Under the MOU, Coherent will develop a supply of 200 mm n-type 4H SiC substrates for Mitsubishi Electric's future SiC power devices manufactured at the new facility.

05:05 EDT Rocket Lab completes second Electron launch for NASA - Rocket Lab completed the second of two dedicated Electron launches to deploy a constellation of tropical cyclone monitoring satellites for NASA. The Coming To A Storm Near You launch lifted-off on May 26 from Rocket Lab Launch Complex 1 on New Zealand's Mahia Peninsula, deploying the final two CubeSats of NASA's TROPICS constellation to orbit. 'Coming To A Storm Near You' is Rocket Lab's second of two TROPICS launches for NASA, following the first launch on May 8th NZST. Like the previous launch, 'Coming To A Storm Near You' deployed a pair of shoebox-sized satellites to low Earth orbit to collect tropical storm data more frequently than other weather satellites. The constellation aims to help increase understanding of deadly storms and improve tropical cyclone forecasts. The TROPICS CubeSats required launch to a specific orbit at an altitude of 550 kilometers and inclination of about 30 degrees, with all four satellites needing to be deployed into their operational orbit within a 60-day period ahead. Rocket Lab has now launched all four satellites across two dedicated launches within 18 days, enabling the TROPICS satellites to settle into their orbits and begin commissioning ahead of the 2023 North American storm season which begins in June. While the TROPICS launches were Rocket Lab's 36th and 37th launches, they were unique from most of the Company's other missions to low Earth orbit due to the 30 degree inclination requirement. To reach such a low inclination from Launch Complex 1, Rocket Lab used Electron's second stage to place the Kick Stage and TROPICS satellites into a circular orbit, and the Kick Stage's Curie engine carried out a plane change maneuver to position the TROPICS satellites at 30 degrees.